Investors may have overestimated just how much Ozempic and Wegovy would be selling by now.The stock's been all the rage since 2021, when the U.S. Food and Drug Administration first approved its Wegovy as a treatment for obesity. Nevertheless, Novo Nordisk (NVO -8.12%) shares are down to the tune of 7.8% as of 11:48 a.m. ET Wednesday, according to data from S&P Global Market Intelligence.Blame weight-loss drug Wegovy's disappointing sales during the recently ended second quarter, mostly. This weakness -- alo ...